Research Disclosures & Disclaimers

This website contains disclosures and disclaimers related to
published UBS Global Research products, including those related to
regulation, potential conflicts of interest as well as those provided
by third-party data providers describing limitations on use of their
products.

Simcere Pharmaceutical Group (2096.HK)*

UBS Rating and Price Target History Chart

Line chart explaining Price target vs Stock Price is described in below table

EQ Rating & Price Target Table

Date	Stock Price (HK$)	Price Target (HK$)	Rating
2022-03-30	11.00	12.50	Buy
2022-09-01	8.31	13.00	Buy
2023-01-31	10.84	14.20	Buy
2023-04-03	8.17	13.40	Buy
2023-07-21	7.55	13.10	Buy
2024-03-15	5.29	8.20	Buy
2024-08-22	5.24	7.40	Buy
2025-03-06	7.97	10.50	Buy
2025-03-26	7.59	10.40	Buy
2025-06-18	10.86	-	No Rating
2025-06-19	10.12	10.40	Buy

Note : Historical Price Targets have been adjusted to account for any stock splits, rights issues and/or dividends which may have occurred for this security. Not Priced: Stock was not priced on the given date. No Rating: Issuer was not rated by UBS on the given day. No Price Target: For this issuer no Price Target was set by UBS on the given day. Issuers with an EQ Rating & Price Target Table are covered by UBS-IB Equity Research Analysts. Issuers without an EQ Rating & Price Target Table are not single stock covered.

* Issuers marked with an asterisk are covered by UBS-IB Equity Research Analysts. Issuers without an asterisk are not single stock covered.